- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 297427, 10 pages
Roots of Erigeron annuus Attenuate Acute Inflammation as Mediated with the Inhibition of NF-κB-Associated Nitric Oxide and Prostaglandin E2 production
1Medical Research Center for Globalization of Herbal Formulation, College of Oriental Medicine, Daegu Haany University, Daegu 706-828, Republic of Korea
2Department of Herbal Pharmaceutical Engineering, Daegu Haany University, Kyung-San, Kyung-Buk 712-715, Republic of Korea
Received 24 October 2012; Revised 10 January 2013; Accepted 15 January 2013
Academic Editor: Ke Ren
Copyright © 2013 Mi Jeong Jo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Erigeron annuus is a naturalized plant belonging to Compositae (asteraceae) family, which is called the annual fleabane, and commonly found at meadows and roadside. This study investigated the anti-inflammatory effects of the extract of E. annuus roots (EER), as assessed by the paw edema formation and histological analysis in rat, and the productions of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines in Raw264.7 murine macrophages. Carrageenan treatment promoted infiltration of inflammatory cells and caused swelling in the hind paw. Oral administrations of EER (0.3 g/kg and 1 g/kg) attenuated acute inflammation similar to the result using dexamethasone (1 mg/kg). Treatment of macrophages with lipopolysaccharide (LPS) simulated inflammatory condition: LPS significantly increased the productions of NO, PGE2, and proinflammatory cytokines. EER suppressed activation of macrophages, preventing the induction of iNOS and COX-2 protein expressions. LPS treatment induced phosphorylation of I-κBα and increased the level of nuclear NF-κB protein, both of which were suppressed by concomitant treatment of EER. In conclusion, EER ameliorated acute inflammation in rats, and the induction of NO, PGE2, and proinflammatory cytokines in Raw264.7 cells. EER’s effects may be associated with its inhibition of NF-κB activation, suggesting its effect on inflammatory diseases.
Inflammation of human body is one of the most important biological responses to harmful stimuli (e.g., pathogens or damaged cells) during the host defense mechanism. Acute inflammatory response initiates pathological process of numerous disorders such as infection, bacterial sepsis, cancer, and chronic inflammation in specific organ (i.e., hepatitis and arthritis) [1–6]. In the progression of inflammation, the representative pathological symptoms are characterized by an increased blood flow to the peripheral tissue by augmentation of vascular permeability, which leads to cellular infiltration and swelling .
Macrophage is one of the most important phagocytic cells and plays a crucial role in the process of inflammation by producing proinflammatory mediators. Lipopolysaccharide (LPS) is the major component of outer membrane of gram-negative bacteria and has the ability to directly activate macrophages to secrete the inflammatory mediators such as NO and PGE2 [8–12]. Nitric oxide (NO) is produced by three distinct isoforms of nitric oxide synthases (NOS) (i.e., neural (nNOS), endothelial (eNOS), and inducible (iNOS)). Among them, iNOS is a key regulator for inducing a large quantity of NO during inflammation and is indicated in many cell types such as macrophage, endothelial, and epithelial cells [13, 14]. PGE2 is also another important inflammatory mediator which is produced from arachidonic acid through the catalytic reaction by COX-2 [15, 16]. It has been shown that iNOS and COX-2 are transcriptionally activated by NF-κB, one of the most important transcription factors regulating the immune responses, cell adhesion, and survival [17–19].
Erigeron annuus (E. annuus) is a naturalized plant belonging to Compositae (Asteraceae) family and commonly found at meadows and roadside. In traditional oriental medicine, E. annuus has been used to treat indigestion, epidemic hepatitis, enteritis, lymphadenitis, and hematuria [20, 21]. However, the effects of E. annuus roots have not been elucidated. In this study, we investigated the potential effect of the extract of E. annuus roots (EERs) on acute inflammation induced by carrageenan injection in rats. Furthermore, this study identified EER as an active component having an ability of the inhibitory effects on LPS-stimulated iNOS and COX-2 expressions as well as TNF-α and IL-1β productions in RAW264.7 macrophages. In view of importance of the inflammation in the process of human disease, these results show the pharmacological effects of EER in terms of the treatment of inflammatory diseases.
2. Materials and Methods
2.1. Preparation of the EER
E. annuus was collected by ourselves in May 2011 from Sangdong, Suseonggu, Daegu, Korea, and identified by Professor Sang Chan, Kim Ph.D. (College of Oriental Medicine, Daegu Haany University, Korea). The roots part of E. annuus were washed twice with water and then dried in the air. EERs were prepared with methanol at room temperature for 72 h. The extract was filtered through a 0.2 μm filter (Nalgene, New York, NY, USA), lyophilized, and stored at −20°C until use. The amount of EERs was estimated by the dried weight of lyophilized EER. The yield of lyophilized EER was 0.89%.
2.2. Analysis of EER
Analysis of EER was performed on an Agilent 6890 gas chromatography equipped with a 5975 GC/MS selective detector (Agilent, CA, USA). Separations were performed in a 30 m length × 0.25 mm i.d. and 0.25 μm film thickness fused silica capillary column HP-5MS (Agilent, CA, USA). The carrier gas was ultrapure helium with a flow of 1 mL/min, and the splitless injector temperature was set as 280°C. The column temperature program was the initial temperature of 70°C for 4 min and increased by 2°C/min 70 to 100°C (held 2 min). After that the temperature was varied from 100 to 200°C at 5°C/min (held 20 min) and increased to 280°C (held 5 min) at 10°C/min, in a total run time of 73 min. Mass spectral analyses were performed using the NIST05 library resident in the computer. Percentage composition was calculated using the area normalization method (see Figure S1 in Supplementary Material available online at http://dx.doi.org/10.1155/2013/297427).
Anti-NF-κB p65 and horseradish peroxidase-conjugated goat antirabbit were supplied from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antiphospho-I-κBα (p-I-κBα), anti-Lamin A, horseradish peroxidase-conjugated antimouse, and antigoat, IgGs were purchased from Cell Signaling (Beverely, MA, USA). Antimurine iNOS was purchased from BD Bioscience (San Jose, CA, USA). Anti-COX-2 antibody was purchased from Cayman (Ann Arbor, Mi, USA). Polyethylene glycol number 400 (PEG) solution, carrageenan, dexamethasone, and other reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
2.4. Animal Experiment
Animal experiments were conducted under the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Daegu Haany University . Sprague-Dawley rats at 4 weeks of age (male, 80–100 g) were provided from Hyochang Sience (Daegu, Korea), acclimatized for 1 week, and maintained in a clean room at the Animal Center for Pharmaceutical Research, College of Oriental Medicine, Daegu Haany University. Animals were caged under the supply of filtered pathogen-free air, commercial rat chow (Purina, Korea), and water ad libitum at a temperature between 20 and 23°C with 12 h light and dark cycles and relative humidity of 50%.
2.5. Carrageenan-Induced Paw Edema
Rats () were randomly divided into four groups, and thus each group consisted of five animals. EER, dissolved in 40% polyethylene glycol (PEG) number 400, was orally administered to rats at the dose of 0.3 or 1 g/kg/day for four consecutive days. Dexamethasone (1 mg/kg/day), an anti-inflammatory drug, was used as a positive control . To induce acute phase inflammation in paw, rats were injected subcutaneously into the right hind paw with a 1% solution of carrageenan dissolved in saline 30 min after last treatment of vehicle or EER. The paw volumes were measured up to 4 h after the injection at intervals of 1 h. The hind paw volume was determined volumetrically by measuring with a plethysmometer (Ugo Basile, VA, Italy). After euthanasia using ether, the hind paw samples were collected.
2.6. Histological Process
The hind paw skins ventrum pedis skins were separated and fixed in 10% neutral buffered formalin, then embedded in paraffin, sectioned (34 μm), and stained with hematoxylin and eosin (H and E) . The histopathological profiles of each sample were observed under light microscope (Nikon, Japan).
The thicknesses of ventrum pedis skins (from epidermis to dermis, keratin layers were excluded) were measured using automated image analyzer (DMI-300 Image Processing, DMI, Korea) under magnification 40 of microscopy (Nikon, Japan) at prepared skin histological samples as mm/paw. The infiltrated inflammatory cells were also counted using automated image analyzer as cells/ of dermis under magnification 200 of microscopy .
2.8. Cell Culture
Raw264.7 cell, a murine macrophage cell line, was obtained from American Type Culture Collection (Rockville, MD, USA). The cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 50 U/mL penicillin, and 50 mg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO2. For all experiments, the cells were grown to 80–90% confluency and were subjected to no more than 20 cell passages. Raw264.7 cells were incubated with 1 μg/mL LPS (Escherichia coli 026:B6, Sigma, St. Louis, MO, USA). The cells were incubated in the medium without 10% FBS for 24 h and then exposed to LPS or LPS + EER for the indicated time periods. EER dissolved in dimethyl sulfoxide was added to the incubation medium 1 h prior to the addition of LPS.
2.9. MTT Cell Viability Assay
The cells were plated at a density of cells per well in a 24-well plate to determine any potential cytotoxicity . Cells were serum starved for 12 h and then treated with EER for the next 24 h. After incubation of the cells, viable cells were stained with MTT (0.5 μg/mL, 4 h). The media were then removed, and the produced formazan crystals in the wells were dissolved by addition of 300 μL dimethyl sulfoxide. Absorbance was measured at 570 nm using a Titertek Multiskan Automatic ELISA microplate reader (Model MCC/340, Huntsville, AL, USA). Cell viability was defined relative to untreated control cells (i.e., viability (% control) 100 (absorbance of treated sample)/(absorbance of control)).
2.10. Assay of Nitrite Production
NO production was monitored by measuring the nitrite content in culture medium . This was performed by mixing the samples with Griess reagent (1% sulfanilamide, 0.1% N-1-naphthylenediamine dihydrochloride, and 2.5% phosphoric acid). Absorbance was measured at 540 nm after incubation for 10 min.
2.11. Enzyme-Linked Immunosorbent Assay (ELISA)
Raw264.7 cells were preincubated with EER for 1 h and continuously incubated with LPS for 24 h . TNF-α, IL-1β (Endogen, Woburn, MA, USA), and PGE2 (RnD Systems, Minneapolis, MN, USA) contents in the culture medium were measured by ELISA using antimouse TNF-α, IL-1β, and PGE2 antibodies and biotinylated secondary antibody according to the manufacturer’s instruction.
2.12. Immunoblot Analysis
Cells were lysed in the buffer containing 20 mm Tris·HCl (pH 7.5), 1% Triton X-100, 137 mm sodium chloride, 10% glycerol, 2 mm EDTA, 1 mm sodium orthovanadate, 25 mm b-glycerophosphate, 2 mm sodium pyrophosphate, 1 mm phenyl methyl sulfonyl fluoride, and 1 mg/mL leupeptin . Cell lysates were centrifuged at 15,000 g for 10 min to remove debris. The immunoreactive bands were visualized using enhanced chemiluminescence (ECL) detection kit (Amersham Biosciences Corp., Piscataway, NJ, USA) according to the manufacturer’s instructions. Eual loading of proteins was verified by actin or lamin immunoblottings.
2.13. Scanning Densitometry
Densitometric measurements of the bands were made using an image analyzing system (Ultra-Violet Products Ltd., Upland, CA, USA). Repeated experiments were separately performed to confirm changes.
2.14. Statistical Analysis
One-way analysis of variance (ANOVA) was used to assess statistical significance of differences among treatment groups. For each statistically significant effect of treatment, the Newman-Keuls test was used for comparisons between multiple group means. The data were expressed as means ± 95% confidence intervals (CI). All statistical tests were two sided.
3.1. Inhibition of Carrageenan-Induced Paw Edema
To verify inhibitory effects of EER on acute inflammation in vivo, we used the carrageenan-induced paw edema model, which is a well-established model for screening the efficacy of anti-inflammatory drugs . Paw edema formation by carrageenan was observed from 1 h and persisted at least up to 4 h after injection (Figure 1). Maximal induction of paw swelling by carrageenan was observed at 3 h. Administration of EER (0.3 and 1 g/kg/day, p.o., for 4 days) inhibited the ability of carrageenan to induce paw swelling. We also confirmed that dexamethasone (1 mg/kg/day, p.o., for 4 days), a positive control, inhibits the edema formation.
3.2. Inhibition of Carrageenan-Induced Acute Inflammation
In addition, we confirmed the effects of EER on histological profiles of ventrum pedis skin stained with H and E. As shown in Figure 2(a), carrageenan successfully induced paw swelling in ventrum pedis in rats. However, pretreatment of EER at the oral doses of 0.3 and 1 g/kg for 4 days significantly blocked the changes of the thickness of ventrum pedis (Figure 2(b)). Moreover, injection of carrageenan markedly increased infiltration of inflammatory cells, which were inhibited by treatment of EER (Figures 2(c) and 2(d)). Dexamethasone also decreased the number of infiltrated inflammatory cells. These results suggest that repression of paw swelling and of infiltration of inflammatory cells by EER may represent an important efficacy in association with the inhibition of acute inflammation in rats.
3.3. Inhibition of LPS-Inducible NO, PGE2, and Proinflammatory Cytokines Production
Next, our studies were extended to determine the effects of EER in vitro. First, we examined any possible toxicity of EER in Raw264.7 cells. In MTT assay, cell viability was not affected by EER treatment up to 30 μg/mL (data not shown). We chose 3–30 μg/mL concentrations of EER to determine the effect of EER on NO accumulation in LPS-stimulated Raw264.7 cells. LPS (1 μg/mL, 24 h) significantly increased NO production, which was markedly inhibited by EER (3, 10, and 30 μg/mL) in a concentration-dependent manner (i.e., 29%–50%) (Figure 3(a)). PGE2 production in LPS-treated Raw264.7 cells was also inhibited by EER (3 and 10 μg/mL) (Figure 3(b)).
Cytokine is known as one of the major mediators in inflammatory responses. To confirm the inhibition of proinflammatory cytokines, we verified the effects of EER on TNF-α and IL-1β productions in Raw264.7 cells. LPS stimulation significantly increased the productions of TNF-α and IL-1β in culture media of Raw264.7 cells (Figure 3(c)). Treatment of EER at 10 μg/mL inhibited the ability of LPS to induce the cytokines accumulation (Figure 3(c)). Moreover, EER treatment alone had no effects on macrophage activation. These results suggest that EER blocked the activation of macrophage cells in terms of inhibition of NO, PGE2, and cytokines.
3.4. Inhibition of LPS-Inducible iNOS and COX-2 Protein Expression
iNOS and COX-2 are key enzymes in the pathophysiological process of inflammation and the induction of inflammatory mediators such as NO and PGE2. Next, we determined the protein expressions of iNOS and COX-2 by western blot analysis. LPS treatment at 1 μg/mL for 18 h significantly induced protein levels of iNOS and COX-2 in Raw264.7 cells (Figure 4(a)). Densitometer analysis revealed that EER treatment (3 and 10 μg/mL) at 1 h prior to LPS significantly inhibited the iNOS and COX-2 protein expressions in Raw264.7 cells (Figure 4(b)).
3.5. Inhibition of LPS-Inducible NF-κB Activation
NF-κB is one of the most important transcription factors for the induction of the inflammatory genes such as iNOS and COX-2 in immune cells stimulated with inflammatory inducers including LPS [17–19]. NF-κB is translocated to the nucleus by phosphorylation of I-κBα and subsequent degradation of I-κBα subunit. Treatment of Raw264.7 cells with EER for 1 h markedly inhibited the nuclear level of NF-κB induced by LPS (Figure 5(a)). Moreover, exposure of LPS decreased the increased phosphorylation of I-κBα protein level at 30 min, which was also blocked subsequent treatment of EER (Figure 5(b)). These results suggest that EER might prevent translocation of NF-κB to the nucleus by inhibiting I-κBα phosphorylation.
E. annuus is called the annual fleabane, which is a plant indigenous to Eastern North America widely found at meadows and roadside . It is well known to be used as the treatment of indigestion, epidemic hepatitis, enteritis, lymphadenitis, and hematuria in traditional oriental medicine [25, 26]. Recently, it has been studied that each part of E. annuus has different pharmaceutical efficacies. The flower extract E. annuus had anti-inflammatory effect through the induction of hemeoxygenase-1, and its leaf extract was shown to have neuroprotective and antioxidant effects against oxidative stress induced by H2O2 [27, 28]. Nevertheless, the scientific proof and mechanistic basis for the effect of E. annuus roots have almost not been studied. In this study, we determined anti-inflammatory effects of EER in vivo and in vitro for the first time.
Swelling is one of the most important symptoms of acute inflammation and characterized by an increase in vascular permeability and infiltration of cells. Therefore, its induction by carrageenan is a well-established model to screen novel anti-inflammatory drug [22, 29, 30]. In our study, carrageenan injection successfully creates acute inflammation in the peripheral tissue, as indicated by increases in the number of inflammatory cells and skin thicknesses in ventrum pedis. Also, carrageenan induced paw swelling during 1–4 h (maximally 3 h) after injection. These results are consistent with previous observations, showing that carrageenan induces infiltration of immune cells and resultantly increased inflammatory response [29, 30]. Next, we assessed the effects of EER in rats injected with carrageenan. Administration of EER inhibited the infiltration of inflammatory cell in the tissue and swelling in the paw skin. These results, here, demonstrate that EER could prevent the acute inflammation in vivo.
The pathology of inflammation is started by complex processes stimulated by the endotoxins such as LPS. In this immune defense mechanism, macrophages play an important role in the progression of the human disorder . LPS can directly activate macrophages, which produce the inflammatory mediators such as NO, eicosanoids, TNF-α, and ILs [9, 10]. TNF-α and IL-1β, the representative proinflammatory cytokines, are small secreted proteins mediating immunity and inflammation. TNF-α can activate macrophages and initiate immune responses by stimulating secretion of other cytokines. IL-1β, mainly synthesized by macrophages, is also inflammatory cytokines which play important roles in the acute phase response.
Here, we evaluated the effects of EER on the accumulations of NO and PGE2 in media of Raw264.7 cells stimulated by LPS. Pretreatment of EER suppressed production of LPS-inducible NO and PGE2. In addition, EER treatment significantly blocked the production of proinflammatory cytokines, TNF-α, and IL-1β. Moreover, it has been shown that carrageenan promotes the release of NO as well as PGE2 in the peripheral tissue . Chuha et al. have also shown that carrageenan stimulates the release of TNF-α and ILs. In view of the inhibitory effects of EER on NO and cytokines productions in vitro and the important role of NO and PGE2 on swelling in vivo, the effects of EER on acute inflammation in rats might result, at least in part, from its inhibition of NO and PGE2 in the tissues.
NO and PGs play key roles in defense mechanisms against xenobiotic stimuli such as infection; it has been perceived that the proteins (i.e., NOS or COX) are main regulators having harmful role in the pathological process of inflammation. Coffey et al. showed that macrophages from iNOS knock-out animals are protected tissue from acute inflammation . In case of eicosanoids, it has been shown that production of a large amount of PGs have detrimental effects in inflammation-related diseases, which were mainly dependent on the COX. Immunoblot analysis enables us to verify that the treatment of EER significantly suppressed the ability of LPS to induce iNOS and COX-2.
NF-κB is one of important transcription factors in terms of regulation of the genes, which were involved in inflammatory and immune responses, cell adhesion, and survival [17, 18, 33]. Degradation of I-κBα by its phosphorylation causes activation of NF-κB, which enables NF-κB itself to translocate into the nucleus to initiate transcription of the target genes. In this study, we assessed immunoblot analysis to show the effects of EER on NF-κB activation. As shown in Figure 5, pretreatment of EER inhibited phosphorylation of I-κBα induced by LPS and resultant degradation of I-κBα (data not shown). Also, EER treatment markedly blocked the nuclear level of NF-κB, showing that the effect of EER on the expression of inflammatory genes might result from the inhibition of NF-κB activation. Moreover, it has been shown that I-κBα is phosphorylated by I-κBα kinase (IKK) complex, which may be activated by a line of kinases (e.g., tyrosine kinase family members and mitogen-activated protein kinases) [34, 35]. It might have value to study the effects of EER on these upstream kinases, which may have the possibility of being a potential pharmacological target of EER.
The chemical compositions of E. annuus have been reported by many researchers. Flower of E. annuus has a large number of phenolic compounds . The three quinic acid derivatives and four flavonoids were isolated from the leaves and stems of E. annuus . The aerial parts or the roots of E. annuus contained sesquiterpenoids, diterpenoid, polyacetylenic compound, -pyrone derivatives, sterols, triterpenoids, monoterpene hydrocarbons, and monoterpene oxygenated components [37, 38]. Among them, it has been shown that sesquiterpenoids, diterpenoid, sterols, and triterpenoids had anti-inflammatory effects [39–46]. Therefore, it remains to be confirmed what is pharmacologically effective ingredient in the EER in terms of anti-inflammation.
In our study, we used two approaches to show the effect of EER: (1) an animal model using carrageenan-induced acute inflammation and (2) a cell model using activated macrophage induced by LPS. Oral administrations of EER attenuated acute inflammation, as indicated by the inhibition of inflammatory cells infiltration and paw swelling induced by carrageenan. Treatment of EER in Raw264.7 cells suppressed the activation of the macrophage by preventing the induction of iNOS and COX-2 protein expressions as well as the productions of NO and PGE2, which is related with its inhibition of NF-κB activation. These findings showing here might help to understand the pharmacology of the roots of E. annuus and offer the possibility of herbal candidate for the treatment of inflammatory disease.
|EER:||Extract of Erigeron annuus root|
|I-κB:||Inhibitor of κB|
|iNOS:||Inducible nitric oxide synthase|
|TNF-α:||Tumor necrosis factor-α.|
Conflict of Interests
The authors declare that they have no competing financial interests.
This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea government (MEST) (no. 2012-0009400).
- A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008.
- G. Brevetti, G. Giugliano, L. Brevetti, and W. R. Hiatt, “Inflammation in peripheral artery disease,” Circulation, vol. 122, no. 18, pp. 1862–1875, 2010.
- S. Hummasti and G. S. Hotamisligil, “Endoplasmic reticulum stress and inflammation in obesity and diabetes,” Circulation Research, vol. 107, no. 5, pp. 579–591, 2010.
- B. N. Lambrecht and H. Hammad, “The role of dendritic and epithelial cells as master regulators of allergic airway inflammation,” The Lancet, vol. 376, no. 9743, pp. 835–843, 2010.
- E. Christaki, S. M. Opal, J. C. Keith et al., “Estrogen receptor β agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study,” Journal of Infectious Diseases, vol. 201, no. 8, pp. 1250–1257, 2010.
- C. Bouffi, C. Bony, G. Courties, C. Jorgensen, and D. Noël, “IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis,” PLoS ONE, vol. 5, no. 12, Article ID e14247, 2010.
- I. Posadas, M. Bucci, F. Roviezzo et al., “Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression,” British Journal of Pharmacology, vol. 142, no. 2, pp. 331–338, 2004.
- C. C. Corriveau and R. L. Danner, “Endotoxin as a therapeutic target in septic shock,” Infectious Agents and Disease, vol. 2, no. 1, pp. 35–43, 1993.
- W. H. Watson, Y. Zhao, and R. K. Chawla, “S-adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor α,” Biochemical Journal, vol. 342, no. 1, pp. 21–25, 1999.
- P. Kubes and D. M. McCafferty, “Nitric oxide and intestinal inflammation,” American Journal of Medicine, vol. 109, no. 2, pp. 150–158, 2000.
- H. Kleinert, P. M. Schwarz, and U. Förstermann, “Regulation of the expression of inducible nitric oxide synthase,” Biological Chemistry, vol. 384, no. 10-11, pp. 1343–1364, 2003.
- Y. W. Kim, R. J. Zhao, S. J. Park et al., “Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-κB-dependent iNOS and proinflammatory cytokines production,” British Journal of Pharmacology, vol. 154, no. 1, pp. 165–173, 2008.
- S. J. Kim, M. S. Ha, E. Y. Choi, J. I. Choi, and I. S. Choi, “Nitric oxide production and inducible nitric oxide synthase expression induced by Prevotella nigrescens lipopolysaccharide,” FEMS Immunology and Medical Microbiology, vol. 43, no. 1, pp. 51–58, 2005.
- Y. Kobayashi, “The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation,” Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1157–1162, 2010.
- S. Moncada, R. M. J. Palmer, and E. A. Higgs, “Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacological Reviews, vol. 43, no. 2, pp. 109–142, 1991.
- S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002.
- S. Ghosh and M. Karin, “Missing pieces in the NF-κB puzzle,” Cell, vol. 109, no. 2, pp. S81–S96, 2002.
- G. Bonizzi and M. Karin, “The two NF-κB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004.
- M. S. Hayden and S. Ghosh, “Signaling to NF-κB,” Genes and Development, vol. 18, no. 18, pp. 2195–2224, 2004.
- C. C. Bennington and D. A. Stratton, “Field tests of density- and frequency-dependent selection in Erigeron annuus (Compositae),” American Journal of Botany, vol. 85, no. 4, pp. 540–545, 1998.
- H. Oh, S. Lee, H. S. Lee et al., “Germination inhibitory constituents from Erigeron annuus,” Phytochemistry, vol. 61, no. 2, pp. 175–179, 2002.
- L. B. Katz, H. M. Theobald, R. C. Bookstaff, and R. E. Peterson, “Characterization of the enhanced paw edema response to carrageenan and dextran in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 230, no. 3, pp. 670–677, 1984.
- H. D. Kim, H. R. Cho, S. B. Moon et al., “Effect of exopolymers from Aureobasidium pullulans on formalin-induced chronic paw inflammation in mice,” Journal of Microbiology and Biotechnology, vol. 16, no. 12, pp. 1954–1960, 2006.
- R. L. C. Handy and P. K. Moore, “A comparison of the effects of L-NAME, 7-NI and L-NIL on caurageenan-induced hindpaw oedema and NOS activity,” British Journal of Pharmacology, vol. 123, no. 6, pp. 1119–1126, 1998.
- D. S. Jang, N. H. Yoo, N. H. Kim et al., “3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis,” Biological and Pharmaceutical Bulletin, vol. 33, no. 2, pp. 329–333, 2010.
- H. Y. Nam, S. J. Dae, L. Y. Jeong et al., “Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity,” Journal of Natural Products, vol. 71, no. 4, pp. 713–715, 2008.
- M. S. Sung, Y. H. Kim, Y. M. Choi, H. M. Han, H. S. Jeong, and J. S. Lee, “Anti-inflammatory effect Erigeron annuus L. Flower extract though heme oxygenase-1 inhibition in Raw264.7 macrophages,” Journal of the Korean Society of Food Science and Nutrition, vol. 40, pp. 1507–1511, 2011.
- C. H. Jeong, H. R. Jeong, G. N. Choi, D. O. Kim, U. Lee, and H. J. Heo, “Neuroprotective and anti-oxidant effects of caffeic acid isolated from Erigeron annuus leaf,” Chinese Medicine, vol. 6, article 25, 2011.
- M. Di Rosa, “Prostaglandins, leucocytes and non steroidal anti inflammatory drugs,” Polish Journal of Pharmacology and Pharmacy, vol. 26, no. 1-2, pp. 25–36, 1974.
- J. Garcia Leme, L. Hamamura, M. P. Leite, and M. Rocha e Silva, “Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating,” British Journal of Pharmacology, vol. 48, no. 1, pp. 88–96, 1973.
- K. Omote, K. Hazama, T. Kawamata et al., “Peripheral nitric oxide in carrageenan-induced inflammation,” Brain Research, vol. 912, no. 2, pp. 171–175, 2001.
- M. J. Coffey, S. M. Phare, and M. Peters-Golden, “Induction of inducible nitric oxide synthase by lipopolysaccharide/interferon gamma and sepsis down-regulates 5-lipoxygenase metabolism in murine alveolar macrophages,” Experimental Lung Research, vol. 30, no. 7, pp. 615–633, 2004.
- E. Jimi and S. Ghosh, “Role of nuclear factor-κB in the immune system and bone,” Immunological Reviews, vol. 208, pp. 80–87, 2005.
- W. C. Huang, J. J. Chen, and C. C. Chen, “c-Src-dependent tyrosine phosphorylation of IKKβ is involved in tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9944–9952, 2003.
- S. A. Trushin, K. N. Pennington, E. M. Carmona et al., “Protein kinase Cα (PKCα) acts upstream of PKCθ to activate IκB kinase and NF-κB in T lymphocytes,” Molecular and Cellular Biology, vol. 23, no. 19, pp. 7068–7081, 2003.
- D. S. Jang, N. H. Yoo, Y. M. Lee, J. L. Yoo, Y. S. Kim, and J. S. Kim, “Constituents of the flowers of Erigeron annuus with inhibitory activity on the formation of advanced glycation end products (AGEs) and aldose reductase,” Archives of Pharmacal Research, vol. 31, no. 7, pp. 900–904, 2008.
- J. Nazaruk and D. Kalemba, “Chemical composition of the essential oils from the roots of Erigeron acris L. and Erigeron annuus (L.) Pers,” Molecules, vol. 14, no. 7, pp. 2458–2465, 2009.
- T. Iijima, Y. Yaoita, and M. Kikuchi, “Two new cyclopentenone derivatives and a new cyclooctadienone derivative from Erigeron annuus (L.) Pers., Erigeron philadelphicus L., and Erigeron sumatrensis Retz,” Chemical and Pharmaceutical Bulletin, vol. 51, no. 7, pp. 894–896, 2003.
- X. Li, M. Yang, Y. F. Han, and K. Gao, “New sesquiterpenes from Erigeron annus,” Planta Medica, vol. 71, no. 3, pp. 268–272, 2005.
- M. K. Jang, H. J. Lee, J. S. Kim, and J. H. Ryu, “A curcuminoid and two sesquiterpenoids from Curcuma zedoaria as inhibitors of nitric oxide synthesis in activated macrophages,” Archives of Pharmacal Research, vol. 27, no. 12, pp. 1220–1225, 2004.
- V. Hernández, M. D. C. Recio, S. Máñz, J. M. Prieto, R. M. Giner, and J. L. Ríos, “A mechanistic approach to the in vivo anti-inflammatory activity of sesquiterpenoid compounds isolated from Inula viscosa,” Planta Medica, vol. 67, no. 8, pp. 726–731, 2001.
- G. W. Hoyle, C. I. Hoyle, J. Chen, W. Chang, R. W. Williams, and R. J. Rando, “Identification of triptolide, a natural diterpenoid compound, as an inhibitor of lung inflammation,” American Journal of Physiology, vol. 298, no. 6, pp. L830–L836, 2010.
- A. Navarro, B. de Las Heras, and A. M. Villar, “Andalusol, a diterpenoid with anti-inflammatory activity from Sideritis foetens Clemen,” Zeitschrift fü r Naturforschung. Section C, vol. 52, no. 11-12, pp. 844–849, 1997.
- D. T. A. Youssef, A. K. Ibrahim, S. I. Khalifa, M. K. Mesbah, A. M. S. Mayer, and R. W. M. Van Soest, “New anti-inflammatory sterols from the red sea sponges Scalarispongia aqabaensis and Callyspongia siphonella,” Natural Product Communications, vol. 5, no. 1, pp. 27–31, 2010.
- B. Singh, P. M. Sahu, and M. K. Sharma, “Anti-inflammatory and antimicrobial activities of triterpenoids from Strobilanthes callosus Nees,” Phytomedicine, vol. 9, no. 4, pp. 355–359, 2002.
- A. I. Huguet, M. Del Carmen Recio, S. Máez, R. M. Giner, and J. L. Ríos, “Effect of triterpenoids on the inflammation induced by protein kinase C activators, neuronally acting irritants and other agents,” European Journal of Pharmacology, vol. 410, no. 1, pp. 69–81, 2000.